Omega Diagnostics confirms deal with UK government to manufacture COVID-19 tests11 Feb 2021 11:37
Omega Diagnostics confirms deal with UK government to manufacture COVID-19 tests https://www.**********.co.uk/articles/omega-diagnostics-confirms-deal-with-uk-government-to-manufacture-covid-19-tests--30b46ee
(ODX ) has confirmed that it has won a contract with the Department of Health and Social Care ("DHSC") to manufacture COVID-19 lateral flow antigen tests, as part of the UK Government's target of producing two million lateral flow tests per day.
The confirmation follows speculation in recent days following a report published by the Financial Times which named the healthcare provider as one of three companies that had been selected by the UK Department of Health to produce additional Covid-19 rapid tests.?
The intention is that as soon as the DHSC has access to a test that has successfully passed a performance evaluation, the test will be licensed for ODX to manufacture. DHSC will loan a number of key pieces of manufacturing equipment to enable ODX to expand its capacity.
By facilitating the necessary expansion in production capability in ODX’s Alva-based facility, this will ensure that the COVID-19 lateral flow tests are made available ‘as soon as possible.’
Omega said it will be able to produce c.2 million tests a week by the end of April when combining the Government-loaned equipment with its own manufacturing equipment.
It also highlighted to investors that it expects that this capacity will be ‘sufficient’ to meet the expected demand for lateral flow COVID-19 antigen tests, with enough remaining capacity to be used for VISITECT® CD4 or COVID-19 antibody tests according to demand.
"We are delighted to formalise our relationship with the UK Government and to utilise our lateral flow test production capacity to support the COVID-19 mass testing programme being rolled out across this country,” said Colin King, Chief Executive of Omega Diagnostics.
Shares in Omega Diagnostics have nearly doubled in value over the past three months from 59p in November 2020. Today, the stock is trading 8.60% higher at 101p following the news.
GBX 4.500
0.000 (0.00%)
Last updated 08:00
King also acknowledged the Group’s recent trading, stating, “I appreciate that trading in our core business has been softer than expected for the current financial year, however the on-going opportunity for growth in CD4 testing and Food Intolerance revenues is unchanged.”
Omega said the significant contribution to its future performance expected as a?result of the DHSC contract above ‘will impact the new financial year ending 31 March 2022.’
The Group’s Food Intolerance division has ‘held up well, despite the impact from pandemic lasting longer than originally thought,’ with sales expected to be in the region of £7.5m for the year ended 31 March 2021, which is a reduction of 19% over the previous year.?
Sign In
Follow the stocks
